ER and post-ER quality control of integral membrane proteins
完整膜蛋白的 ER 和 ER 后质量控制
基本信息
- 批准号:10176534
- 负责人:
- 金额:$ 36.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-06-01 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:26S proteasomeAddressBiochemicalCellsCytoplasmCytosolDevelopmentDiseaseEndoplasmic ReticulumEndoplasmic Reticulum Degradation PathwayEukaryotaEventFoundationsGenetic ScreeningGoalsHealthIntegral Membrane ProteinLeadLinkMembraneMembrane ProteinsModelingMolecularMolecular ChaperonesNamesOrganellesPaperPathway interactionsPeptide HydrolasesPlayProcessProteinsPublicationsPublishingQuality ControlResearchResistanceRoleStressTechnologyUbiquitinUbiquitinationdisease-causing mutationexperimental studyextracellularhuman diseasein vitro Assaymembermethod developmentmisfolded proteinpolypeptideprogramsprotein aggregationprotein foldingproteotoxicitytool
项目摘要
Approximately one-third of all newly synthesized proteins in eukaryotes enter the endoplasmic
reticulum (ER). Once associated with this compartment, these nascent polypeptides are post-
translationally processed, acquire their native confirmations, oligomerize, and are sorted for
extracellular secretion or delivery to other organelles. However, many disease-causing
mutations compromise protein folding and maturation, which in turn can generate aggregation-
prone species. To off-set the catastrophic effects that accompany the accumulation of protein
aggregates, misfolded protein substrates are: (i) selected by molecular chaperones associated
with the ER, (ii) modified with ubiquitin, (iii) delivered to the cytoplasm via a process known as
retrotranslocation, and (iv) degraded by the 26S proteasome. Brodsky and colleagues named
this pathway ER associated degradation (ERAD), and over the past 21 years many of the
molecular mechanisms underlying this sequence of events were defined in the Brodsky lab. To
date, ~80 human diseases are linked to the ERAD pathway and >1,200 publications have been
authored on various aspects of this pathway. Ongoing efforts are defining the
pathophysiological foundation of several ERAD-related disorders. In parallel, members of the
Brodsky lab have revealed how key components orchestrate each step during ERAD. In the
past 5 years, the lab has published 64 papers, and tools and technologies were developed that
provide an unprecedented view of the mechanisms that lead to the selection, ubiquitination,
retrotranslocation, and degradation of diverse substrates. Nevertheless, recent discoveries
dictate that more challenging research directions are pursued: By necessity, these next efforts
will require additional method development and a pursuit of longer-term goals. Specific
questions that the research program will address include: What biochemical features define an
ERAD substrate? Which factors are sufficient to drive the retrotranslocation of ERAD substrates,
some of which are aggregation-prone? Do ER-associated proteases function in tandem with the
26S proteasome to destroy substrates that are stably integrated into the ER membrane, and
thus might be retrotranslocation resistant? And, how are retrotranslocated membrane proteins—
which can reside in the cytosol after being liberated from the ER—retained in a soluble state?
Answers to these questions, which lie at the core of research in the field, will significantly
advance an understanding of how cellular health is maintained in the face of proteotoxic stress
as well as how ERAD-associated diseases arise and might be rectified.
在真核生物中,大约三分之一的新合成的蛋白质进入内质
网状结构(ER)。一旦与这个隔室联系在一起,这些新生多肽就是后
翻译处理,获得它们的本机确认,寡聚,并被排序
胞外分泌或输送到其他细胞器。然而,许多致病因素
突变损害了蛋白质的折叠和成熟,进而可以产生聚集-
易受感染的物种。以抵消伴随蛋白质积累的灾难性影响
聚集体,错误折叠的蛋白质底物:(I)由相关的分子伴侣选择
利用内质网,(Ii)用泛素修饰,(Iii)通过称为
逆转易位,以及(Iv)被26S蛋白酶体降解。Brodsky和他的同事被命名为
这条内质网相关降解(ERAD)的途径,在过去的21年里,许多
布罗德斯基实验室对这一系列事件背后的分子机制进行了定义。至
到目前为止,大约有80种人类疾病与ERAD途径有关,已经发表了1200篇出版物
关于这条道路的各个方面的作者。正在进行的努力正在定义
几种ERAD相关疾病的病理生理学基础。同时,委员会的成员
Brodsky实验室揭示了关键组件如何在ERAD期间协调每一步。在
在过去的5年里,该实验室发表了的论文,并开发了
提供了一种前所未有的视角来了解导致选择、泛素化、
不同底物的反向移位和降解。然而,最近的发现
决定追求更具挑战性的研究方向:不可避免地,这些下一步的努力
将需要额外的方法开发和追求更长期的目标。特定的
该研究计划将解决的问题包括:哪些生化特征定义了
Erad底物?哪些因素足以驱动ERAD底物的逆转移位,
其中一些是易于聚合的?内质网相关的蛋白水解酶是否与
26S蛋白酶体,破坏稳定整合到内质网膜上的底物,以及
因此可能对易位有抵抗力?以及,逆转膜蛋白是如何-
从内质网中释放出来后,什么可以留在胞浆中--以可溶的状态保留?
这些问题的答案,是该领域研究的核心,将显著地
加深对如何在蛋白质毒性应激下维持细胞健康的理解
以及与ERAD相关的疾病是如何产生和可能纠正的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY L. BRODSKY其他文献
JEFFREY L. BRODSKY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY L. BRODSKY', 18)}}的其他基金
The role of FIT2 in VLDL assembly, hepatic triglyceride homeostasis, and lipoprotein atherogenicity
FIT2 在 VLDL 组装、肝甘油三酯稳态和脂蛋白致动脉粥样硬化中的作用
- 批准号:
10638637 - 财政年份:2023
- 资助金额:
$ 36.84万 - 项目类别:
Interinstitutional Program in Cell and Molecular Biology: A Graduate Training Path to Promote Traditional and Non-Traditional Professional Outcomes
细胞和分子生物学机构间项目:促进传统和非传统专业成果的研究生培训路径
- 批准号:
10421289 - 财政年份:2020
- 资助金额:
$ 36.84万 - 项目类别:
Interinstitutional Program in Cell and Molecular Biology: A Graduate Training Path to Promote Traditional and Non-Traditional Professional Outcomes
细胞和分子生物学机构间项目:促进传统和非传统专业成果的研究生培训路径
- 批准号:
10192522 - 财政年份:2020
- 资助金额:
$ 36.84万 - 项目类别:
ER and post-ER quality control of integral membrane proteins
完整膜蛋白的 ER 和 ER 后质量控制
- 批准号:
10626023 - 财政年份:2019
- 资助金额:
$ 36.84万 - 项目类别:
ER and Post-ER Quality Control of Integral Membrane Proteins
完整膜蛋白的 ER 和 ER 后质量控制
- 批准号:
10798491 - 财政年份:2019
- 资助金额:
$ 36.84万 - 项目类别:
ER and post-ER quality control of integral membrane proteins
完整膜蛋白的 ER 和 ER 后质量控制
- 批准号:
10428489 - 财政年份:2019
- 资助金额:
$ 36.84万 - 项目类别:
Modulating Hsp70-dependent proteostasis in Alzheimer's Disease
调节阿尔茨海默病中 Hsp70 依赖性蛋白质稳态
- 批准号:
10118403 - 财政年份:2019
- 资助金额:
$ 36.84万 - 项目类别:
FASEB SRC on Protein Folding in the Cell
FASEB SRC 关于细胞中蛋白质折叠的研究
- 批准号:
8720195 - 财政年份:2014
- 资助金额:
$ 36.84万 - 项目类别:
2009 Stress Proteins in Growth, Development, and Disease Gordon Research Conferen
2009 年生长、发育和疾病中的应激蛋白戈登研究会议
- 批准号:
7663377 - 财政年份:2009
- 资助金额:
$ 36.84万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 36.84万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 36.84万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 36.84万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 36.84万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 36.84万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 36.84万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 36.84万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 36.84万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 36.84万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 36.84万 - 项目类别:
Research Grant